Lack of gp130 expression in hepatocytes attenuates tumor progression in the DEN model

Gp130 Signaling Promotes Development of Acute Experimental Colitis by Facilitating Early Neutrophil/Macrophage Recruitment and Activation

(2014) L. E. Sander et al.   JOURNAL OF IMMUNOLOGY

TNFR1 determines progression of chronic liver injury in the IKKγ/Nemo genetic model

(2013) F J Cubero et al.   CELL DEATH AND DIFFERENTIATION

Peptide-Functionalized Gold Nanorods Increase Liver Injury in Hepatitis

(2012) Matthias Bartneck et al.   ACS Nano

Foxa1 and Foxa2 Are Essential for Sexual Dimorphism in Liver Cancer

(2012) Zhaoyu Li et al.   CELL

Constitutively Active Mutant gp130 Receptor Protein from Inflammatory Hepatocellular Adenoma Is Inhibited by an Anti-gp130 Antibody That Specifically Neutralizes Interleukin 11 Signaling

(2012) J. Sommer et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Serine 727 phosphorylation of STAT3: An early change in mouse hepatocarcinogenesis induced by neonatal treatment with diethylnitrosamine

(2012) Masaaki Miyakoshi et al.   MOLECULAR CARCINOGENESIS

DNA damage induces reactive oxygen species generation through the H2AX-Nox1/Rac1 pathway

(2012) M A Kang et al.   Cell Death & Disease

STAT3 activation in monocytes accelerates liver cancer progression

(2011) Wen-Yong Wu et al.   BMC CANCER

Impairment of hepatic growth hormone and glucocorticoid receptor signaling causes steatosis and hepatocellular carcinoma in mice

(2011) Kristina M. Mueller et al.   HEPATOLOGY

Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling

(2011) Simon A. Jones et al.   JOURNAL OF CLINICAL INVESTIGATION

IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcinoma

(2011) Fang-Ming Gu et al.   Molecular Cancer

Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5

(2011) Xiang-Ping Yang et al.   NATURE IMMUNOLOGY

Tumor initiation and progression in hepatocellular carcinoma: risk factors, classification and therapeutic targets

(2010) Tamara Severi et al.   ACTA PHARMACOLOGICA SINICA

Hepatocyte IKKβ/NF-κB Inhibits Tumor Promotion and Progression by Preventing Oxidative Stress-Driven STAT3 Activation

(2010) Guobin He et al.   CANCER CELL

DNA Damage-Induced Cytotoxicity Is Dissociated from BRCA1's DNA Repair Function but Is Dependent on Its Cytosolic Accumulation

(2010) H. Wang et al.   CANCER RESEARCH

IL-6, a risk factor for hepatocellular carcinoma: FLLL32 inhibits IL-6-Induced STAT3 phosphorylation in human hepatocellular cancer cells

(2010) Yan Liu et al.   CELL CYCLE

NF-κB and STAT3 – key players in liver inflammation and cancer

(2010) Guobin He et al.   CELL RESEARCH

gp130 at the nexus of inflammation, autoimmunity, and cancer

(2010) J. S. Silver et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Experimental mouse models for hepatocellular carcinoma research

(2009) Femke Heindryckx et al.   INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY

Loss of STAT5 causes liver fibrosis and cancer development through increased TGF-β and STAT3 activation

(2009) Atsushi Hosui et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Tyrosine dephosphorylation of H2AX modulates apoptosis and survival decisions

(2009) Peter J. Cook et al.   NATURE

STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34pos cells into tumor-competent dendritic cells

(2008) P. A. Cohen et al.   BLOOD

Defective DNA strand break repair causes chromosomal instability and accelerates liver carcinogenesis in mice

(2008) Narci C. Teoh et al.   HEPATOLOGY

Molecular targeted therapies in hepatocellular carcinoma

(2008) Josep M. Llovet et al.   HEPATOLOGY

Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours

(2008) Sandra Rebouissou et al.   NATURE

Role of sex steroid receptors in pathobiology of hepatocellular carcinoma

(2008) Mamta Kalra et al.   WORLD JOURNAL OF GASTROENTEROLOGY